Activation of the NKG2D axis is also considered a potential target in the treatment of metabolically associated fatty liver disease (MAFLD) and nonalcoholic steatohepatitis. This evidence concerns the gene KLRK1 and metabolic dysfunction-associated steatohepatitis.